Findings

What do systematic reviews say?

8 questions · 8 findings · 1 reviews · Airways

Sort:Best matchNewest Highest certainty Download CSV

No studies found 0 · 0%GRADE not reported 0 · 0%Very low 1 · 12.5%Low 1 · 12.5%Moderate 6 · 75%High 0 · 0%

SCS treatment for 7 or fewer days vs SCS treatment

Length of hospitalisation (days) · exacerbations of COPD

1 finding from 1 review

Different durations of corticosteroid therapy for exacerbations of chronic obstructive pulmonary disease 2018 · Cochrane Headline outcomes only
no estimate extracted
3 studies · 421 participants
Moderate

SCS treatment for 7 or fewer days vs SCS treatment

Treatment failure Need for additional treatment · exacerbations of COPD

SCS treatment for 7 or fewer days showed no clear difference in treatment failure Need for additional treatment compared with SCS treatment (moderate certainty).

1 finding from 1 review

Different durations of corticosteroid therapy for exacerbations of chronic obstructive pulmonary disease 2018 · Cochrane Headline outcomes only
OR 0.72 [0.36, 1.46]
4 studies · 457 participants
Moderate

SCS treatment for 7 or fewer days vs SCS treatment

Relapse New acute exacerbation or COPD‐related admission · exacerbations of COPD

SCS treatment for 7 or fewer days showed no clear difference in relapse New acute exacerbation or COPD‐related admission compared with SCS treatment (moderate certainty).

1 finding from 1 review

Different durations of corticosteroid therapy for exacerbations of chronic obstructive pulmonary disease 2018 · Cochrane Headline outcomes only
OR 1.04 [0.7, 1.56]
4 studies · 478 participants
Moderate

SCS treatment for 7 or fewer days vs SCS treatment

Adverse drug effect—hyperglycaemia · exacerbations of COPD

SCS treatment for 7 or fewer days showed no clear difference in adverse drug effect—hyperglycaemia compared with SCS treatment (moderate certainty).

1 finding from 1 review

Different durations of corticosteroid therapy for exacerbations of chronic obstructive pulmonary disease 2018 · Cochrane Headline outcomes only
OR 0.99 [0.64, 1.53]
2 studies · 345 participants
Moderate

SCS treatment for 7 or fewer days vs SCS treatment

Adverse drug effects Gastrointestinal tract bleeding, symptomatic gastrointestinal reflux, symptoms of congestive heart failure or ischaemic heart disease, sleep disturbance, fractures, depression · exacerbations of COPD

SCS treatment for 7 or fewer days showed no clear difference in adverse drug effects Gastrointestinal tract bleeding, symptomatic… compared with SCS treatment (low certainty).

1 finding from 1 review

Different durations of corticosteroid therapy for exacerbations of chronic obstructive pulmonary disease 2018 · Cochrane Headline outcomes only
OR 0.88 [0.46, 1.7]
5 studies · 503 participants
Low

SCS treatment for 7 or fewer days vs SCS treatment

All‐cause mortality · exacerbations of COPD

SCS treatment for 7 or fewer days showed no clear difference in mortality compared with SCS treatment (moderate certainty).

1 finding from 1 review

Different durations of corticosteroid therapy for exacerbations of chronic obstructive pulmonary disease 2018 · Cochrane Headline outcomes only
OR 0.91 [0.4, 2.06]
2 studies · 336 participants
Moderate

SCS treatment for 7 or fewer days vs SCS treatment

FEV1 · exacerbations of COPD

1 finding from 1 review

Different durations of corticosteroid therapy for exacerbations of chronic obstructive pulmonary disease 2018 · Cochrane Headline outcomes only
no estimate extracted
4 studies · 187 participants
Very low

SCS treatment for 7 or fewer days vs SCS treatment

QoL · exacerbations of COPD

1 finding from 1 review

Different durations of corticosteroid therapy for exacerbations of chronic obstructive pulmonary disease 2018 · Cochrane Headline outcomes only
no estimate extracted
1 study · 271 participants
Moderate